AI Business Tools: IQVIA’s Playbook for Real ROI

A six-day market selloff reportedly erased nearly US$830 billion from software and services stocks, driven by fresh anxiety that new AI tools could “displace” established enterprise businesses. One of the companies pulled into that narrative was IQVIA, the healthcare data and clinical research provider, after it guided 2026 adjusted EPS to US$12.55–US$12.85 (below the US$12.95 analyst average cited by LSEG) and watched its shares drop more than 8% on the day.

The interesting part isn’t the stock move. It’s the argument happening underneath it: Is AI replacing service businesses—or rewarding the ones with proprietary data, strong workflows, and clear client outcomes? IQVIA’s CEO Ari Bousbib was blunt on the earnings call, calling displacement fears “really frustrating” and pointing to IQVIA’s “largest proprietary healthcare information assets” as the moat general-purpose AI can’t copy.

For this AI Business Tools Singapore series, I’m using the IQVIA moment as a case study for a problem I see every week: companies buy AI because everyone else is buying AI, then struggle to prove impact. IQVIA’s situation highlights what actually matters—data advantage, use-case discipline, and measurable business outcomes—and it’s directly relevant to Singapore teams rolling out AI for marketing, operations, and customer engagement.

Why analysts are skeptical about AI’s business impact

Answer first: Analysts aren’t “anti-AI.” They’re worried that AI benefits are being captured by new tool providers, while incumbent service firms pay the cost (pricing pressure, slower growth, and client churn).

The skepticism comes from a pattern:

• General-purpose AI is getting good enough at summarising, drafting, analysing, and basic decision support—tasks that used to justify large service fees.
• Switching costs are dropping. If a new AI product can do 70% of the job at 20% of the cost, some buyers will try it.
• Narratives move faster than evidence. Markets often price “threat” faster than companies can show “proof.”

IQVIA got caught in that crossfire. Even though it beat fourth-quarter expectations (profit of US$3.42 per share on US$4.36B revenue, per the Reuters write-up), the questions were about the future: will clients still pay for what IQVIA does if AI tooling accelerates?

The myth: “AI will replace your business”

Here’s the thing about displacement talk: it’s usually a shortcut for a more precise question:

If AI makes the workflow cheaper, faster, and easier, what part of your offering is still defensible?

Companies that can’t answer that get commoditised. Companies that can answer it win share.

IQVIA’s stance: proprietary data beats generic AI

Answer first: IQVIA’s defence is straightforward: AI models are only as valuable as the data and workflows they’re built on, and IQVIA claims a proprietary healthcare dataset advantage that general tools can’t recreate.

Bousbib’s core point—paraphrased into plain business terms—is:

• A general AI model can generate outputs.
• It cannot magically create owned clinical, claims, trial, and real-world evidence datasets with consistent governance, provenance, and permissions.

That matters because in regulated industries (healthcare, finance, telecom), executives don’t buy “AI.” They buy:

• Traceability: Where did this recommendation come from?
• Compliance: Can we defend the process to auditors and regulators?
• Accuracy at the edge cases: Does it work on messy real-world data, not just clean demos?

A practical translation for Singapore businesses

You may not have IQVIA-scale data assets, but you can build a smaller, sharper moat:

• Your first-party customer data (transactions, service logs, tickets, web/app behavior)
• Your process data (SOPs, playbooks, product specs)
• Your domain feedback loops (sales objections, lost-deal reasons, NPS comments)

The companies that win with AI business tools in Singapore aren’t the ones with the fanciest model. They’re the ones with the cleanest inputs and tightest feedback loop.

What “AI strategy” should look like when ROI is under scrutiny

Answer first: A credible AI strategy ties models to workflows, workflows to metrics, and metrics to financial outcomes—within 90 days.

If you want AI that survives CFO scrutiny (and investor scrutiny, if you’re public), you need more than pilots. Here’s what works.

1) Pick use cases where AI reduces paid hours or increases conversion

Start with use cases that have simple unit economics. Examples relevant to Singapore teams:

• Customer support triage + response drafting to reduce average handling time
• Sales call summarisation + next-step generation to increase follow-up rate
• Marketing content ops (briefs, variations, localisation) to increase output per marketer
• Procurement and finance document processing to reduce cycle time and errors

A good rule: if you can’t write the ROI on a whiteboard, it’s not ready.

Simple ROI formula:

• (Hours saved × fully loaded hourly cost) + (incremental revenue × gross margin) − AI costs

2) Treat data like a product (not a byproduct)

IQVIA’s entire defence rests on data assets. For most companies, the biggest AI blocker is boring:

• inconsistent naming
• missing fields
• messy ticket tags
• scattered documents

If you want AI outcomes, you need AI-ready inputs.

A lightweight “data product” checklist:

• One owner per dataset (Sales Ops, CX Ops, Finance)
• Defined schema and naming conventions
• Access rules by role
• Change log (what changed, when, why)

3) Build guardrails before you scale

Most companies get this wrong: they scale the tool first and add controls later.

Guardrails that should exist before roll-out:

• Human-in-the-loop for customer-facing outputs
• Approved knowledge sources (“answer only from these docs”)
• PII redaction in prompts and logs
• Audit trail for AI-assisted decisions (especially in regulated sectors)

If you’re in Singapore, you also need to align AI deployments with internal governance and applicable data protection requirements (don’t bolt this on after a mishap).

Best practices Singapore teams can copy from IQVIA (without IQVIA budgets)

Answer first: You don’t need a massive AI lab to copy the pattern. You need focus: protect your data advantage, choose measurable workflows, and prove impact fast.

A 30-60-90 day AI rollout plan (practical and realistic)

Day 1–30: Choose one workflow and instrument it

• Pick one high-volume process (support tickets, sales follow-ups, invoice matching)
• Define baseline metrics (time per task, error rate, CSAT, conversion rate)
• Run AI in “assist mode” only (humans approve outputs)

Day 31–60: Improve the inputs and narrow the scope

• Clean the top 20% of documents that drive 80% of questions
• Add a feedback mechanism (“good answer / bad answer + reason”)
• Create a short playbook so staff use the tool consistently

Day 61–90: Prove ROI and decide scale

• Calculate hours saved and quality improvements
• Identify failure modes (hallucinations, policy violations, brand tone issues)
• Decide: scale, pivot use case, or stop

This approach prevents the most common “AI pilot trap”: lots of demos, no durable lift.

What to measure (so the AI impact is undeniable)

Pick one primary metric and two supporting metrics.

Examples:

• Customer support: primary = average handling time; supporting = first contact resolution, CSAT
• Sales ops: primary = speed-to-lead; supporting = meeting set rate, pipeline influenced
• Marketing: primary = cost per qualified lead; supporting = content cycle time, CTR

When investors questioned IQVIA, it wasn’t because it had “no AI.” It was because markets want confidence that AI translates to defensible revenue and margins.

People also ask: “Will AI replace service businesses in Singapore?”

Answer first: AI will replace some tasks, not the entire business—unless your business is only those tasks.

If you sell time (hours), AI pressure is real. If you sell outcomes (reduced churn, faster onboarding, fewer errors, better compliance), AI can strengthen your value—because you can deliver outcomes faster and with more consistency.

A blunt positioning test:

• If your client can describe your value as “they make slides and reports,” you’re exposed.
• If your client describes your value as “they reduce regulatory risk and speed decisions,” you’re defensible.

IQVIA is betting that its proprietary data and embedded role in drug development workflows keep it in the second category.

What this means for “AI Business Tools Singapore” buyers

AI hype cycles are loud in February 2026, but the buying criteria are getting clearer. The winners will be companies that can show three things:

1. A unique data advantage (even if it’s just well-governed first-party data)
2. Workflow adoption (AI used daily, not occasionally)
3. Measured ROI (time saved, conversion improved, risk reduced)

If you’re evaluating AI business tools in Singapore right now, don’t ask vendors for a demo first. Ask for an ROI plan tied to your process and your numbers. The tool is the easy part.

AI doesn’t kill businesses. Commoditised workflows kill businesses.

If you want help turning one business process into a measurable AI win, map your workflow, identify your proprietary inputs, and pick metrics you can defend in a board meeting. What’s the one process in your company where saving 10 minutes per transaction would show up immediately on your P&L?

Source for the IQVIA news context: https://www.channelnewsasia.com/business/iqvia-backs-ai-strategy-analysts-question-impact-business-5910261 (Reuters via CNA, published Feb 5, 2026).